GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Capital Expenditure

Fusion Antibodies (LSE:FAB) Capital Expenditure : £0.24 Mil (TTM As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Fusion Antibodies's cash flow for capital expenditures for the six months ended in Sep. 2023 was £0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2023 was £0.24 Mil.

Fusion Antibodies Capital Expenditure Historical Data

The historical data trend for Fusion Antibodies's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Capital Expenditure Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -1.38 -0.11 -0.37 -0.26 -0.11

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.07 -0.36 0.24 -

Fusion Antibodies Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies (LSE:FAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Capital Expenditure
Comparable Companies
LSE:RENE LSE:NFX LSE:PYC LSE:GENF AQSE:INC LSE:EVG LSE:APTA LSE:IXI LSE:CIZ LSE:OCTP OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Website
https://www.fusionantibodies.com
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor • 10-21-2022